|1.||Thota, Sreekanth: 3 articles (03/2013 - 11/2007)|
|2.||Keppler, Bernhard K: 3 articles (08/2008 - 06/2007)|
|3.||Groessl, Michael: 2 articles (01/2014 - 05/2008)|
|4.||Dyson, Paul J: 2 articles (01/2014 - 11/2008)|
|5.||Gambino, Dinorah: 2 articles (06/2013 - 10/2011)|
|6.||Moreno, Virtudes: 2 articles (06/2013 - 10/2011)|
|7.||De Clercq, Erik: 2 articles (03/2013 - 11/2007)|
|8.||Yerra, Rajeshwar: 2 articles (03/2013 - 01/2012)|
|9.||Balzarini, Jan: 2 articles (03/2013 - 11/2007)|
|10.||Messori, Luigi: 2 articles (06/2010 - 11/2008)|
09/01/2009 - "Among these drugs, ruthenium compounds have been showing promising results to treat tumors and represent an important development of new antitumor therapy. "
06/01/2015 - "Arene ruthenium compounds exhibited higher activity compared to that of Cp*Rh/Cp*Ir in inhibiting the cancer cells growth and pathogenic bacteria. "
05/01/2010 - "Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. "
05/01/2010 - "Ruthenium compounds theoretically possess unique biochemical features allowing them to accumulate preferentially in neoplastic tissues and to convert to their active state only after entering tumor cells. "
11/13/2008 - "On the basis of the obtained data, different mechanisms of binding/inhibition appear to be operative; remarkably the selectivity of the ruthenium compounds toward solid metastatic tumors also correlates to the observed trends. "
06/11/2007 - "Surprisingly, they show reasonable antiproliferative activity in vitro in two human cell lines, HT-29 (colon carcinoma) and SK-BR-3 (mammary carcinoma), when compared with analogous ruthenium compounds. "
08/18/2008 - "5a, 7a, and 9a were found to possess remarkable antiproliferative activity in vitro against A549 (non-small cell lung carcinoma), CH1 (ovarian carcinoma), and SW480 (colon carcinoma) cells, which was compared with that of related ruthenium compounds trans-[RuCl 2(Hazole) 4]Cl, where Hazole = Hpz (5b), Hind (6b), Him (7b), and Hbzim (9b)."
11/01/2007 - "Ruthenium compounds (Ru1-Ru12) showed promising biological activity especially in decreasing tumor volume and viable ascites cell counts. "
01/01/2012 - "The test ruthenium compounds at the doses 2 and 4 mg/kg body weight showed promising biological activity, especially in decreasing tumor volume, viable ascites cell counts and body weights. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
|3.||DNA (Deoxyribonucleic Acid)
|8.||Staphylococcal Protein A (A, Protein)
|10.||Dimethyl Sulfoxide (DMSO)